A

Amgen

Makes biotech medicines for serious illnesses

Biostatistical Programming Manager

Full-TimeUpdated on 10/24/2026
No salary listed
Senior
Bachelor's, Master's
Hyderabad, Telangana, India
In PersonOn-site in Hyderabad, India.
Biology & BiotechQuantitative Biology & Biostatistics

About the job

Requirements
  • A BA/BSc or higher degree in biostatistics, statistics, mathematics, computer science, or other related quantitative or scientific subjects, with at least 6 years of statistical programming experience in a clinical development environment.
  • Have a thorough understanding of clinical trial processes, from data collection to analysis reporting.
  • Have a proven record of superior statistical programming and problem-solving skills within a clinical development environment.
  • Have prior experience and the ability to lead and manage statistical programmers in successful and timely completion of all programming-related activities, including preparing data and programming specifications, for a study end-to-end.
  • Have in-depth knowledge of the latest CDISC SDTM, ADaM, and Define standards and a strong ability to implement all aspects of those standards.
  • Have advanced analysis and reporting skills in SAS, including SAS/STAT packages.
  • Have experience with data quality and compliance check tools.
  • Have excellent project management skills and the ability to lead multiple projects effectively.
  • Have excellent oral and written English communication skills.
  • Be able to work effectively and successfully in a globally dispersed team environment with cross-cultural partners.
  • Be willing and able to provide guidance to team members on technical and process questions.
Responsibilities
  • Lead one or more studies or projects end-to-end and assume all responsibilities of the Study Lead Programmer.
  • Set programming strategy for studies and projects and ensure timelines, quality, and compliance of all deliverables.
  • Lead and manage specific programming tasks assigned to the team, such as programming activities for an integrated analysis involving multiple studies for regulatory submissions.
  • Participate in establishing programming scope for deliverables with statisticians and the study team.
  • Participate in establishing detailed timelines to ensure timely delivery of programming deliverables for a study or project.
  • Create and maintain programming-related specifications, including SDTM and ADaM, for studies and projects.
  • Represent Global Statistical Programming at the Clinical Study Team.
  • Attend meetings and provide programming input into cross-functional study start-up activities, including CRF development, database specifications review, database development, IVRS specification review, and data quality check specifications.
  • Initiate cross-functional team meetings as necessary.
  • Perform significant hands-on statistical programming, particularly for the most challenging deliverables.
  • Manage individual programmer work assignments to ensure timely, high-quality deliverables.
  • Provide technical leadership and guidance for the study programming team.
  • Coordinate and monitor data issue reporting and resolution.
  • Coordinate with other Study Lead Programmers to provide consistent deliverables across studies within a product.
  • Manage technical aspects of projects, such as creating and managing computing environments and lookup tables.
  • Provide training and guidance to other programmers.
  • Assume product-level responsibilities as delegated by the Global Programming Lead or Programming Execution Lead.
Desired Qualifications
  • Have an MSc or higher degree in statistics, biostatistics, mathematics, or related quantitative or scientific subjects.
  • Be familiar with open-source programming tools such as R and Python, automation platforms, and emerging technologies in statistical programming.
  • Have prior regulatory submission experience for drug approval.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

PR Newswire
Oct 26th, 2026
Amgen appoints former Yum! Brands CEO David Gibbs to its board

Amgen has appointed David W. Gibbs to its board of directors, effective immediately. He will serve on the Audit Committee and the Compensation and Management Development Committee. Gibbs recently retired as president and chief executive officer of Yum! Brands, owner of Taco Bell and Kentucky Fried Chicken. As chief executive from 2020 to 2025, he led its digital transformation and expanded it to nearly 61,000 locations. He has sat on the board of Under Armour since 2021 and PepsiCo since 2026. "His experience creating direct relationships with customers will help inform how we prepare for future launches," said Robert A. Bradway, Amgen's chairman and chief executive officer. The board now has 13 directors, 12 of them independent.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.

Yahoo Finance
Oct 25th, 2026
Amgen vs Gilead: Which biotech dividend stock is the better buy, with yields of 2.2% and 2.1%?

Amgen and Gilead Sciences, two of the few big biotech companies that pay dividends, suit different kinds of income investors, according to a comparison by The Motley Fool's Keith Speights. Amgen offers a forward dividend yield above 2.2%, against slightly below 2.1% for Gilead. Gilead has the lower payout ratio, at 43.5% versus 60.9%, and the cheaper valuation: 15.6 times forward earnings against 16.7. Amgen's product sales grew 9% year over year in its latest quarter, against 8% for Gilead. It has 17 drugs on track to be blockbusters this year, versus eight for Gilead, and 29 late-stage programs. Speights favours Amgen for yield and growth, and Gilead for safety and value.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.